Topical Drug Delivery Market

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027

Report Code: PH 7545 May, 2022, by marketsandmarkets.com

[307 Pages Report] The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. Growth in this market is majorly driven by the high incidence fo burn injuries, increasing number of smokers around the world,  growing prevalence of diabetes, and advancements in transdermal drug delivery systems.

Operating Room/OR Integration Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Topical Drug Delivery Market

During the COVID-19 pandemic surge, self-medication was a usual pattern for consuming medicines during COVID-19. Due to the pandemic, many treatment facilities and single doctor clinics were closed, depriving common people of timely medical assistance. The pandemic has encouraged self-medication. Topical corticosteroids were the most used therapeutic strategies for self-medication. The most used topical drugs were anti-acne preparations, corticosteroids, combinations (corticosteroids, antibiotics, and antifungals), moisturizers, and barrier creams. Self-medication has increased the demand for over-the-counter and topical drugs, positively impacting the topical drug delivery market.

During COVID-19, one of the main symptoms was running nose, cold, and cough. Nasal sprays used during COVID-19 were effective in curing nasal congestion. For example, Amcyte Pharma launched its Nasitrol nasal spray (topical solution) for sinus irrigation. The nasal cavity and the rhino pharynx were the key sites of the initial replication of SARS-CoV-2. The spray is formulated to reduce the viral load in upper respiratory airways, preventing viruses from proliferating and spreading into the lungs. This increase in nasal sprays that can suppress the viral load during COVID-19 has increased the demand for topical sprays and foams used to relieve the nasal congestion caused by the virus.

Topical Drug Delivery Market Dynamics

Driver: High Incidence of burn injuries

The treatment of burn injuries is one of the major application areas of topical drugs. Topical antimicrobial agents such as Fenistil (GSK), Sulfamylon cream (Mylan), Bactroban (GSK), and Silvadene (Pfizer) are considered the first line of treatment for burn injuries in patients.

According to the Lancet Public Health, in 2021, burns were one of the major causes of disability, with more than 8 million disability-adjusted life-years (DALYs). The high incidence of burn injuries in major regional segments across the globe has resulted in sustained demand for topical drugs for effective burn treatment and management. Many topical antimicrobial agents are used to cure burns. An antimicrobial agent such as silver sulfadiazine cream is used to treat wound infections in second and third-degree burns patients. However, patients with severe burns or burns over a large area are treated in a hospital. There are many other antibiotic ointments for burns, such as over-the-counter options for an uncomplicated burn.

Restraint: Continuous irritation on skin and allergies caused by topical drugs

Many topical formulations are available over the counter and include antibacterial & antifungal preparations, anti-inflammatory & pain-relief preparations, and cleansing & moisturizing agents. Topical corticosteroids are used in many inflammatory rashes. However, in some cases, topical corticosteroid sensitivity produces allergic reactions. Usually, this is seen as a failure to cure dermatitis or to worsen existing dermatitis treated with corticosteroids. Very rarely, corticosteroid allergy may appear as an eczematous rash in a completely different area of the body from the original dermatitis. Some topical antibiotics may also cause contact allergies, such as bacitracin, which is used to prevent minor skin injuries such as cuts, scrapes, and burns. Benzocaine and salicylate are some of the active ingredients in topical formulations which causes allergies. These allergies caused by such drugs can be diagnosed by a patch test that can detect contact allergens. Allergy to topical medications is more common in older patients, but some patients with pre-existing skin conditions are at a higher risk of developing allergic reactions to topical medications. These allergies caused by the topical drugs are one of the limitations of the usage of such medicines. In most cases, patients adopt another type of drug delivery system or go for other forms of medicine.

Opportunity: Rising demand for self-administration and home care

Self-administration of drugs within home care settings is expected to provide significant growth opportunities for players operating in the topical drug delivery market. This is mainly due to the rising geriatric population and closing regular OPDs for a few months during COVID-19. Elderly individuals form a large consumer base for topical drugs in-home care. This factor also increases the need for inhalation, topical, and transdermal drug products designed to cater to the needs of caregivers and patients. Transdermal drug delivery enhances the ease of administration of drugs as it uses a transdermal patch that can be easily self-administered. It provides suitable and painless self-administration for patients. This approach helps reduce healthcare costs by reducing the duration of hospital stays. Also, in the case of transdermal patches, caregivers can easily determine if a patch is placed securely. This acts as one of the main opportunities to increase the demand for transdermal patches, boosting the growth of topical drug deliveries.

Challenge: Topical formulation for drugs with limited plasma concentration

Topical drug delivery refers to the application of medication to the surface of the skin or within the layers of skin or mucous membrane. Skin acts as a barrier and prevents the penetration of many APIs, even though it is an ideal site to achieve both local and systemic effects via the delivery of drug substances. However, drugs that have a larger particle size are not easily absorbed through the skin. To facilitate skin absorption, the molecular weight of a compound should be under 500 Dalton when developing drug substances for use in topical dermatological therapies. These high molecular weight drugs are poorly lipid-soluble and cannot achieve the desired therapeutic effect and action. Percutaneous absorption decreases with high molecular weight. This decreased therapeutic effect of topical medicines limits the adoption of topical drug delivery.

The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, by product in 2021

Based on products, the topical drug delivery the market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. In 2021, the semi-solid formulations segment accounted for the largest share in the market. The large share of this segment is attributed to suitability to APIs with low density, more stable in atmospheric conditions than liquid and solid forms, and rise in personalized medicine as they have a unique composition and increased absorptive properties. These dosage forms are non-dehydrating and make no modifications to skin functioning.

The dermal drug delivery segment accounted for the largest share of the topical drug delivery market, by route of administration in 2021

Based on the route of administration, the market is segmented into dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The large share of the dermal drug delivery market segment can largely be attributed to pain free self-administration for patients, advantageous for drugs with shorter half-lives or narrow therapeutic indices, and elimination of frequent administration of drugs and plasma level peaks and valleys associated with oral dosing and injections to maintain a constant drug concentration.

The home care settings segment accounted for the largest share of the topical drug delivery market, by facility of use in 2021

Based on the facility of use, the market is segmented into home care settings, hospitals & clinics, burn centers, and other facilities. The large share of home care settings segment can be attributed to advantages for long-term therapy, better convenience in comparison with inpatient care, and improvement in medical adherence and treatment outcomes. The increasing geriatric population across the globe and the growing need for self- administration of drugs are some other important factors influencing the growth of the home care settings segment.

North America accounted for the largest share of the topical drug delivery market in 2021

In 2021, North America accounted for the largest share the topical drug delivery market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the rising prevalence of target health conditions, the increasing preference for pain-free drug delivery solutions, the growing prevalence of skin diseases, an increasing number of smokers around the world, rising advancements in transdermal patches, and the high demand for drugs that can be self-administered.

North America: Topical Drug Delivery Market Snapshot

Topical Drug Delivery Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Major players in the topical drug delivery market are Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, Route of Administration, and Facility of Use

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).

The study categories the topical drug delivery Market based on product, route of administration, facility of use, and regional and global level.

Global Topical Drug Delivery Market, by Product

  • Semi-Solid Formulations
    • Creams
    • Ointments
    • Lotions
    • Gel
    • Pastes
  • Liquid Formulations
    • Suspensions
    • Solutions
  • Solid Formulations
    • Powders
    • Suppositories
  • Transdermal Products
    • Transdermal Patches
    • Transdermal Semi-Solids

Global Topical Drug Delivery Market, by Route of Administration

  • Dermal Drug Delivery
  • Ophthalmic Drug Delivery
  • Rectal Drug Delivery
  • Vaginal Drug Delivery
  • Nasal Drug Delivery

Global Topical Drug Delivery Market, by Facility of Use

  • Home Care Settings
  • Hospitals & Clinics
  • Burn Centers
  • Other Facilities

Global Topical Drug Delivery Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In 2022, Galderma and Taro Pharmaceutical Industries Ltd. signed a definitive agreement for Taro to acquire Alchemee, which is formerly The Proactiv Company, from Galderma. This agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv brand. This agreement will add Proactiv to Taro’s broad portfolio of prescription and over-the-counter dermatology products.
  • In 2021, GlaxoSmithKline plans to build a new global campus and innovation center in Weybridge. This campus will house the global headquarters for the new Consumer Healthcare business, including an innovation center (made up of R&D laboratories and the Consumer Healthcare Shopper Science lab) and the company’s global support function teams based in the UK.
  • In 2020, Teva Pharmaceuticals Industries Ltd. expanded in Japan, it was a new strategy for its local commercial operations as it will focus on commercializing complex generics, specialty assets, and other pipeline opportunities.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 36)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION AND SCOPE
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKETS COVERED
                    FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED
    1.3 CURRENCY
           TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
    1.4 STAKEHOLDERS
    1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
                               FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS
    2.2 MARKET SIZE ESTIMATION
           FIGURE 6 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
           FIGURE 7 TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
           FIGURE 8 PHARMACEUTICAL SALES APPROACH
           FIGURE 9 TOP-DOWN APPROACH
           FIGURE 10 CAGR PROJECTIONS
           FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2022–2027): IMPACT ON MARKET GROWTH & CAGR
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 12 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 STUDY ASSUMPTIONS
    2.6 LIMITATIONS
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT
           TABLE 2 RISK ASSESSMENT: TOPICAL DRUG DELIVERY MARKET

3 EXECUTIVE SUMMARY (Page No. - 54)
    FIGURE 13 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)
    FIGURE 14 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD BILLION)
    FIGURE 15 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022 VS. 2027 (USD BILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET

4 PREMIUM INSIGHTS (Page No. - 58)
    4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
           FIGURE 17 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE MARKET GROWTH
    4.2 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY (2021)
           FIGURE 18 SEMI-SOLID FORMULATIONS TO DOMINATE LATIN AMERICA MARKET IN 2021
    4.3 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH IN MARKET DURING FORECAST PERIOD
    4.4 TOPICAL DRUG DELIVERY MARKET, BY REGION (2020–2027)
           FIGURE 20 NORTH AMERICA TO DOMINATE MARKET IN 2027
    4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 62)
    5.1 INTRODUCTION
    5.2 PRICING ANALYSIS
           TABLE 3 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 High prevalence of skin diseases
                    5.2.1.2 Increase in self-medication as a popular practice in dermatology
                    5.2.1.3 High prevalence of topical prescription therapy for dry eye diseases
                    5.2.1.4 Switching from conventional needle injections to transdermal patches
                    5.2.1.5 High incidence of burn injuries
                    5.2.1.6 Growing prevalence of diabetes
           5.2.2 RESTRAINTS
                    5.2.2.1 Continuous irritation of skin and allergies caused by topical drugs
                    5.2.2.2 Preference for alternative modes of drug delivery
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising demand for self-administration and home care
                    5.2.3.2 Delivery of biologics through transdermal route
                    5.2.3.3 Topical vehicles used in cosmetic industry
           5.2.4 CHALLENGES
                    5.2.4.1 Topical formulations for drugs with limited plasma concentration
                    5.2.4.2 Increasing number of drug failures and product recalls
    5.3 PORTER’S FIVE FORCES ANALYSIS
           5.3.1 NEW ADVANCEMENT IN TRANSDERMAL DRUG DELIVERY SYSTEM
           5.3.2 ADOPTION OF TELEDERMATOLOGY
    5.4 PATENT ANALYSIS
           TABLE 4 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.5 MARKET DYNAMICS
    5.6 INDUSTRY TRENDS
           TABLE 5 REGULATORY SCENARIO, BY COUNTRY
    5.7 KEY CONFERENCES & EVENTS IN 2022-2023
           FIGURE 22 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
    5.8 IMPACT OF COVID-19
           FIGURE 23 PHARMACEUTICAL DRUG DELIVERY MARKET ECOSYSTEM
    5.9 REGULATORY ANALYSIS
    5.10 VALUE CHAIN ANALYSIS
           TABLE 6 REGIONAL PRICING ANALYSIS OF TOPICAL DRUGS, 2021 (USD)
    5.11 ECOSYSTEM MAPPING
           TABLE 7 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF SUPPLIERS
           5.11.4 BARGAINING POWER OF BUYERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 TECHNOLOGY ANALYSIS
           5.12.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
                     FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2011– APRIL 2022)
           5.12.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
                     FIGURE 25 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2011–APRIL 2022)
                     FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY (JANUARY 2011–APRIL 2022)
                     TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN TOPICAL DRUG DELIVERY MARKET, 2021–2022

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT (Page No. - 84)
    6.1 INTRODUCTION
           TABLE 9 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
    6.2 SEMI-SOLID FORMULATIONS
           TABLE 10 KEY TOPICAL DRUG DELIVERY SEMI-SOLID FORMULATIONS AVAILABLE
           TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
           6.2.1 OINTMENTS
                    6.2.1.1 Ointments to be widely used in analgesic indications
                               TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2020–2027 (USD BILLION)
           6.2.2 CREAMS
                    6.2.2.1 Creams to be most widely used formulation due to better absorption
                               TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2020–2027 (USD BILLION)
           6.2.3 LOTIONS
                    6.2.3.1 Easy administration of lotions to drive demand
                               TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2020–2027 (USD BILLION)
           6.2.4 GELS
                    6.2.4.1 Faster drug release and greater patient acceptability to drive gels market
                               TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2020–2027 (USD BILLION)
           6.2.5 PASTES
                    6.2.5.1 Topical pastes to treat and prevent skin irritation
                               TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2020–2027 (USD BILLION)
    6.3 LIQUID FORMULATIONS
           TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
           TABLE 20 KEY LIQUID FORMULATIONS AVAILABLE
           6.3.1 SUSPENSIONS
                    6.3.1.1 Higher rate of bioavailability and controlled onset of action to support market growth
                               TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2020–2027 (USD BILLION)
           6.3.2 SOLUTIONS
                    6.3.2.1 Topical solutions with soluble chemicals to dissolve in various solvents
                               TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2020–2027 (USD BILLION)
    6.4 SOLID FORMULATIONS
           TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
           TABLE 25 KEY SOLID FORMULATIONS AVAILABLE
           6.4.1 POWDERS
                    6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel powders market
                               TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2020–2027 (USD BILLION)
           6.4.2 SUPPOSITORIES
                    6.4.2.1 Suppositories require suitable base to ensure drug compatibility and stability
                               TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES , BY COUNTRY, 2020–2027 (USD BILLION)
    6.5 TRANSDERMAL PRODUCTS
           TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2020–2027 (USD BILLION)
           TABLE 30 KEY TRANSDERMAL PRODUCTS AVAILABLE
           6.5.1 TRANSDERMAL PATCHES
                    6.5.1.1 Transdermal patches to offer increased drug permeability across skin
                               TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2020–2027 (USD BILLION)
           6.5.2 TRANSDERMAL SEMI-SOLIDS
                    6.5.2.1 Transdermal semi-solids to offer fast drying on application site
                               TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS, BY COUNTRY, 2020–2027 (USD BILLION)

7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 107)
    7.1 INTRODUCTION
           TABLE 33 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
    7.2 DERMAL DRUG DELIVERY
           7.2.1 NANO-SIZED DRUG CARRIER SYSTEMS TO BE STUDIED TO OVERCOME DRUG PENETRATION LIMITATION
                    TABLE 34 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
    7.3 OPHTHALMIC DRUG DELIVERY
           7.3.1 MICROEMULSION-BASED FORMULATIONS LEAD TO BETTER OCULAR DRUG ADSORPTION
                    TABLE 35 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
    7.4 VAGINAL DRUG DELIVERY
           7.4.1 RICH AND COMPLEX NETWORK OF CAPILLARIES OF UPPER VAGINA TO CREATE SYSTEMIC DRUG DELIVERY SYSTEM
                    TABLE 36 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
    7.5 RECTAL DRUG DELIVERY
           7.5.1 RECTAL ADMINISTRATION TO ENABLE BOTH LOCAL AND SYSTEMIC THERAPY OF DRUGS
                    TABLE 37 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
    7.6 NASAL DRUG DELIVERY
           7.6.1 NASAL DELIVERY ROUTE OFFERS QUICK ONSET OF DRUG ACTION AND CONVENIENCE AS COMPARED TO PARENTERAL ROUTE
                    TABLE 38 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)

8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE (Page No. - 118)
    8.1 INTRODUCTION
           TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
    8.2 HOMECARE SETTINGS
           8.2.1 HOMECARE TO DOMINATE MARKET DURING FORECAST PERIOD
                    TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2020–2027 (USD BILLION)
    8.3 HOSPITALS & CLINICS
           8.3.1 TOPICAL ANAESTHETICS TO BE ADOPTED FOR VARIOUS MEDICAL AND SURGICAL SUB-SPECIALTIES
                    TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD BILLION)
    8.4 BURN CENTERS
           8.4.1 TOPICAL ANTIMICROBIAL FORMULATIONS FOR BURN-RELATED INJURIES TO DRIVE MARKET GROWTH
                    TABLE 42 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2020–2027 (USD BILLION)
    8.5 OTHER FACILITIES
           TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2020–2027 (USD BILLION)

9 TOPICAL DRUG DELIVERY MARKET, BY REGION (Page No. - 126)
    9.1 INTRODUCTION
           FIGURE 27 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           TABLE 44 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2020–2027 (USD BILLION)
    9.2 NORTH AMERICA
           FIGURE 28 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
           TABLE 45 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
           TABLE 46 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
           TABLE 47 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 48 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 49 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 50 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 51 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
           TABLE 52 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.2.1 US
                    9.2.1.1 Rising prevalence of skin diseases alongside approval and launch of innovative topical formulations to propel market growth
                               TABLE 53 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 54 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 55 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 56 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 57 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 58 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 59 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.2.2 CANADA
                    9.2.2.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
                               TABLE 60 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 61 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 62 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 63 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 64 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 65 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 66 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
    9.3 EUROPE
           TABLE 67 RECENT DEVELOPMENTS IN EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2019–2022
           TABLE 68 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
           TABLE 69 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
           TABLE 70 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 71 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 73 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 74 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
           TABLE 75 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.3.1 GERMANY
                    9.3.1.1 Growing focus of pharmaceutical companies on topical products development and increasing target diseases to drive market growth
                               TABLE 76 DEVELOPMENTS AND PRODUCT LAUNCHES IN TOPICAL DRUG DELIVERY IN GERMANY, 2019–2022
                               TABLE 77 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 78 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 79 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 80 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 81 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 82 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 83 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.3.2 UK
                    9.3.2.1 Increasing developments by top players and demand for pain-free treatment to drive market growth
                               TABLE 84 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 85 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 86 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 87 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 88 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 89 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 90 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.3.3 FRANCE
                    9.3.3.1 Rising prevalence of diabetes and increasing geriatric population to support market growth
                               TABLE 91 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 92 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 93 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 94 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 95 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 96 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 97 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.3.4 ITALY
                    9.3.4.1 Rising number of smokers to propel transdermal patches demand
                               TABLE 98 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 99 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 100 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 101 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 102 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 103 ITALY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 104 ITALY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.3.5 SPAIN
                    9.3.5.1 Growing diabetic patients to drive market growth
                               TABLE 105 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 106 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 107 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 108 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 109 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 110 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 111 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.3.6 SWITZERLAND
                    9.3.6.1 Rising geriatric population and emerging players focusing on topical drugs development to drive market growth
                               TABLE 112 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 113 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 114 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 115 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 116 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 117 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 118 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.3.7 REST OF EUROPE
                    TABLE 119 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                    TABLE 120 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 121 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 122 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 123 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 124 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                    TABLE 125 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
    9.4 ASIA PACIFIC
           FIGURE 29 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
           TABLE 126 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
           TABLE 127 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
           TABLE 128 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 129 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 130 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 131 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 132 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
           TABLE 133 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.4.1 CHINA
                    9.4.1.1 Prevalence of diabetes and increase in pharmaceutical R&D investments to drive market growth
                               TABLE 134 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 135 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 136 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 137 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 138 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 139 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 140 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.4.2 JAPAN
                    9.4.2.1 Increasing number of product approvals and growing focus of local players on topical formulations R&D to support market growth
                               TABLE 141 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 142 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 143 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 144 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 145 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 146 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 147 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.4.3 INDIA
                    9.4.3.1 Rising awareness among healthcare providers and patients alongside increasing focus on noninvasive methods of drug delivery to drive market growth
                               TABLE 148 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 149 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 150 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 151 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 152 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 153 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 154 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Increasing number of smokers to drive market growth
                               TABLE 155 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 156 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 157 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 158 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 159 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 160 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 161 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.4.5 REST OF ASIA PACIFIC
                    TABLE 162 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                    TABLE 163 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 164 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 165 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 166 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 167 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                    TABLE 168 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
    9.5 LATIN AMERICA
           TABLE 169 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
           TABLE 170 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
           TABLE 171 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 172 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 173 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 174 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
           TABLE 175 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
           TABLE 176 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.5.1 BRAZIL
                    9.5.1.1 High prevalence of diabetes to propel market growth
                               TABLE 177 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 178 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 179 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 180 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 181 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 182 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 183 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.5.2 MEXICO
                    9.5.2.1 Increasing prevalence of glaucoma to drive market growth
                               TABLE 184 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                               TABLE 185 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 186 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 187 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 188 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                               TABLE 189 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                               TABLE 190 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
           9.5.3 REST OF LATIN AMERICA
                    TABLE 191 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                    TABLE 192 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 193 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 194 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 195 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 196 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                    TABLE 197 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 GROWING PREVALENCE OF BURN INJURIES AND INCREASING EXPENDITURE ON HEALTHCARE TO DRIVE MARKET GROWTH
                    TABLE 198 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                    TABLE 199 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 200 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 201 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
                    TABLE 202 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 203 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
                    TABLE 204 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 204)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
     10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 30 REVENUE ANALYSIS OF TOP PLAYERS IN TOPICAL DRUG DELIVERY MARKET
     10.4 MARKET SHARE ANALYSIS
             FIGURE 31 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2021
             TABLE 205 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
     10.5 COMPETITIVE LEADERSHIP MAPPING
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                        FIGURE 32 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
     10.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 DYNAMIC COMPANIES
             10.6.3 STARTING BLOCKS
             10.6.4 RESPONSIVE COMPANIES
                        FIGURE 33 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS (2021)
     10.7 COMPANY FOOTPRINT
             TABLE 206 COMPANY FOOTPRINT: TOPICAL DRUG DELIVERY MARKET
             10.7.1 PRODUCT FOOTPRINT OF MAJOR PLAYERS
                        TABLE 207 PRODUCT FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
             10.7.2 ROUTE OF ADMINISTRATION FOOTPRINT OF TOPICAL DRUG DELIVERY MARKET
                        TABLE 208 ROUTE OF ADMINISTRATION FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
             10.7.3 FACILITY OF USE IN TOPICAL DRUG DELIVERY MARKET
                        TABLE 209 FACILITY OF USE FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
             10.7.4 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN TOPICAL DRUG DELIVERY MARKET
                        TABLE 210 GEOGRAPHIC FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
     10.8 COMPETITIVE SCENARIO
             10.8.1 PRODUCT LAUNCHES
                        TABLE 211 PRODUCT LAUNCHES, JANUARY 2019–APRIL 2022
             10.8.2 DEALS
                        TABLE 212 DEALS, JANUARY 2019–APRIL 2022
             10.8.3 OTHER DEVELOPMENTS
                        TABLE 213 OTHER DEVELOPMENTS, JANUARY 2019–APRIL 2022

11 COMPANY PROFILES (Page No. - 222)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
     11.1 KEY PLAYERS
     11.2 OTHER PLAYERS
             11.1.1 GLENMARK PHARMACEUTICALS LTD.
                        TABLE 214 GLENMARK PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
                        FIGURE 34 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
             11.1.2 GALDERMA
                        TABLE 215 GALDERMA: BUSINESS OVERVIEW
             11.1.3 JOHNSON & JOHNSON PRIVATE LIMITED
                        TABLE 216 JOHNSON & JOHNSON PRIVATE LIMITED: BUSINESS OVERVIEW
                        FIGURE 35 JOHNSON & JOHNSON PRIVATE LIMITED: COMPANY SNAPSHOT (2021)
             11.1.4 GLAXOSMITHKLINE PLC.
                        TABLE 217 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
                        FIGURE 36 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT (2021)
             11.1.5 BAUSCH HEALTH COMPANIES INC.
                        TABLE 218 BAUSCH HEALTH COMPANIES INC.: BUSINESS OVERVIEW
                        FIGURE 37 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2021)
             11.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
                        TABLE 219 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
                        FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2021)
             11.1.7 CIPLA
                        TABLE 220 CIPLA: BUSINESS OVERVIEW
                        FIGURE 39 CIPLA: COMPANY SNAPSHOT (2021)
             11.1.8 BAYER AG
                        TABLE 221 BAYER AG: BUSINESS OVERVIEW
                        FIGURE 40 BAYER AG: COMPANY SNAPSHOT (2021)
             11.1.9 VIATRIS INC. (MYLAN N.V.)
                        TABLE 222 VIATRIS INC.: BUSINESS OVERVIEW
                        FIGURE 41 VIATRIS INC.: COMPANY SNAPSHOT (2021)
             11.1.10 3M
                        TABLE 223 3M: BUSINESS OVERVIEW
                        FIGURE 42 3M: COMPANY SNAPSHOT (2021)
             11.1.11 MERCK & CO., INC.
                        TABLE 224 MERCK & CO., INC.: BUSINESS OVERVIEW
                        FIGURE 43 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
             11.1.12 CRESCITA THERAPEUTICS INC.
                        TABLE 225 CRESCITA THERAPEUTICS INC.: BUSINESS OVERVIEW
                        FIGURE 44 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2021)
             11.1.13 NOVARTIS INTERNATIONAL AG
                        TABLE 226 NOVARTIS INTERNATIONAL: BUSINESS OVERVIEW
                        FIGURE 45 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2021)
             11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        TABLE 227 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
                        FIGURE 46 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2021)
             11.1.15 PFIZER INC.
                        TABLE 228 PFIZER INC.: BUSINESS OVERVIEW
                        FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT (2021)
             11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
                        TABLE 229 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
                        FIGURE 48 TEVA PHARMACEUTICALS: COMPANY SNAPSHOT (2021)
             11.1.17 BRISTOL MYERS SQUIBB
                        TABLE 230 BRISTOL MYERS SQUIBB: BUSINESS OVERVIEW
                        FIGURE 49 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2021)
             11.1.18 LEAD CHEMICAL CO., LTD.
                        TABLE 231 LEAD CHEMICAL CO., LTD.: BUSINESS OVERVIEW
             11.1.19 PURDUE PHARMA L.P.
                        TABLE 232 PURDUE PHARMA L.P.: BUSINESS OVERVIEW
             11.1.20 LAVIPHARM
                        TABLE 233 LAVIPHARM: BUSINESS OVERVIEW
             11.1.21 ABBVIE INC.
                        TABLE 234 ABBVIE INC.: BUSINESS OVERVIEW
                        FIGURE 50 ABBVIE INC.: COMPANY SNAPSHOT (2021)
     12.1 INSIGHTS FROM INDUSTRY EXPERTS
             11.2.1 CMP PHARMA, INC.
             11.2.2 ENCORE DERMATOLOGY, INC.
             11.2.3 PROSOLUS INC.
             11.2.4 RUSAN PHARMA LTD.
     12.2 DISCUSSION GUIDE
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

12 APPENDIX (Page No. - 298)
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.4 AVAILABLE CUSTOMIZATIONS
     12.5 RELATED REPORTS
     12.6 AUTHOR DETAILS 
  

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the topical drug delivery market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side and demand side are detailed below. Industry experts such as CEOs, presidents, vice presidents, directors, marketing directors, marketing managers, and related executives from various key companies and organizations in the topical drug delivery  industry were interviewed to obtain and verify both the qualitative and quantitative aspects of this research study. A robust primary research methodology has been adopted to validate the contents of the report and fill in the gaps.

A breakdown of the primary respondents is provided below:

Topical Drug Delivery Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the revenue share analysis, pharmaceutical sales approach, primary interviews, and top-down approach (assessment of Individual shares of each topical drug delivery product, route of administration, and facility of use).

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, and forecast the topical drug delivery market based on product, route of administration, facility of use, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall topical drug delivery market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
  • To estimate the market size and growth potential of the market segments with respect to five key regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players operating in the topical drug delivery market and comprehensively analyze their revenue shares and core competencies
  • To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, collaborations, divestiture, divestment, spin-off, expansions, joint ventures, and acquisitions in the topical drug delivery market
  • To benchmark players in the market using the “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product strategy within the topical drug delivery market
  • To evaluate and analyze the overall impact of COVID-19 on the topical drug delivery market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolio of each company

Geographic Analysis

  • Further breakdown of the Rest of Europe topical drug delivery market into the Netherlands, Belgium, and others.
  • Further breakdown of the Middle East & Africa topical drug delivery market into Saudi Arabia, UAE, and others.

Company Information

  • Detailed analysis and profiling of additional market players (up to five)
Topical Drug Delivery Market Size,  Share & Growth Report
Report Code
PH 7545
Published ON
May, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status